ReviewThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2026
The Neuropsychiatric Disturbances of Delirium: A Review of Syndromes and Their Treatment.
Review in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glutamate carboxypeptidase II activation in astrocytes mediates glymphatic impairment and cognitive vulnerability in the aging brain following surgery.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Broadly analogous to the behavioral and psychological symptoms that plague dementia, the neuropsychiatric disturbances (NPD) of delirium pose significant burdens to patients, their loved ones, and clinicians. Moreover, these disturbances are often the most salient aspect of delirium, causing distress and placing patients and those around them at risk of harm. The field's limited understanding of delirium's NPD could also be a key reason why the pharmacology of delirium remains underdeveloped. In this narrative review, we propose clinically relevant neuropsychiatric syndromes in delirium, along with provisional definitions. We then discuss evidence for potential pharmacological and nonpharmacological interventions for each, both within the context of delirium and in other conditions, especially where these syndromes also occur in dementia. Candidate syndromes include excessive psychomotor activity and the related akathisia; inadequate psychomotor activity, either as reduced arousal or as avolition; psychosis, including perceptual disturbances and erroneous beliefs; emotional disturbances, either as affective dysregulation or as anxious distress; catatonia; and sleep-wake disturbances. The NPD of delirium should be differentiated from the global cognitive impairment of delirium as they often warrant independent clinical attention. The failure to tailor treatments to specific syndromes-for instance, treating akathisia in delirium with an antipsychotic, leading to greater behavioral activation-stands not only to prolong distress but also to worsen clinical outcomes. These syndromes deserve greater awareness and conceptual refinement to inform clinical management and to identify novel avenues for research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.